SymBio Pharmaceuticals

TYO: 4582

Market CapJPY77211.8m

Last Close JPY1997

SymBio Pharmaceuticals is a Japanese specialty pharma company focused on oncology and hematology. It markets Treakisym (bendamustine) in Japan and in-licensed two liquid formulations from Eagle Pharmaceuticals in 2017; brincidofovir was licensed from Chimerix in 2019.

More SymBio Pharmaceuticals content >

Investment summary

SymBio is a speciality pharma focused on Asia-Pacific markets and has the Japanese rights to multiple formulations of Treakisym (bendamustine). Treakisym iv was approved for r/r low-grade NHL/MCL in 2010 and in 2016 for CLL and first-line low-grade NHL/MCL. SymBio has in-licensed liquid formulations for injection that will give Treakisym patent protection to 2031; a clinical trial is underway of the rapid-infusion liquid formulation. The company recently received a label expansion to r/r diffuse large B-cell lymphoma. Finally, the company filed an IND in March 2021 to begin Phase II studies on brincidofovir.

Y/E Dec
Revenue (¥m)
PBT (¥m)
EPS (¥)
P/E (x)
P/CF (x)
2019A 2837.8 (4263.5) (4249.5) (183.72) N/A N/A
2020A 2987.1 (4441.4) (4513.5) (137.10) N/A N/A
2021E 9227.8 1561.2 1508.4 27.02 74.4 N/A
2022E 11483.8 2069.6 2017.5 37.29 53.9 N/A
Industry outlook

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operational leverage.

Last updated on 03/08/2021
Content on SymBio Pharmaceuticals
View more
Register to receive research on SymBio Pharmaceuticals as it is published
Share price graph
Balance sheet
Forecast net cash (¥m) 4792.4
Forecast gearing ratio (%) N/A
Price performance
Actual (16.2) 52.9 348.4
Relative* (14.3) 52.7 263.1
52-week high/low ¥2423.0/¥337.0
*% relative to local index
Key management
Fuminori Yoshida Representative Director, President & CEO